首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1015826篇
  免费   75439篇
  国内免费   7759篇
耳鼻咽喉   13652篇
儿科学   25259篇
妇产科学   24269篇
基础医学   143271篇
口腔科学   29832篇
临床医学   92288篇
内科学   195872篇
皮肤病学   20026篇
神经病学   76794篇
特种医学   39939篇
外国民族医学   140篇
外科学   160322篇
综合类   32890篇
现状与发展   31篇
一般理论   237篇
预防医学   66764篇
眼科学   23804篇
药学   81411篇
  71篇
中国医学   6927篇
肿瘤学   65225篇
  2021年   10177篇
  2019年   8940篇
  2018年   12036篇
  2017年   9854篇
  2016年   10331篇
  2015年   12923篇
  2014年   16838篇
  2013年   21613篇
  2012年   30272篇
  2011年   32051篇
  2010年   19012篇
  2009年   17459篇
  2008年   28685篇
  2007年   30065篇
  2006年   30786篇
  2005年   29865篇
  2004年   27274篇
  2003年   26099篇
  2002年   25314篇
  2001年   56507篇
  2000年   58558篇
  1999年   49324篇
  1998年   12357篇
  1997年   11012篇
  1996年   10778篇
  1995年   9964篇
  1994年   9158篇
  1993年   8187篇
  1992年   36154篇
  1991年   34490篇
  1990年   33257篇
  1989年   32312篇
  1988年   29358篇
  1987年   28559篇
  1986年   26517篇
  1985年   25322篇
  1984年   17917篇
  1983年   15211篇
  1982年   7835篇
  1979年   15811篇
  1978年   10598篇
  1977年   9052篇
  1976年   7871篇
  1975年   8628篇
  1974年   10466篇
  1973年   9858篇
  1972年   9357篇
  1971年   8852篇
  1970年   8426篇
  1969年   7923篇
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
61.
62.
63.
骨碎补是历代临床常用中药,具有疗伤止痛、补肾强骨、消风祛斑等功效。其主要含黄酮、苯丙素、三萜、酚酸及其苷等类化学成分,现代研究表明骨碎补具有抗骨质疏松、促进骨折愈合、促软骨再生、护牙健齿、保护肾功能、抗炎、防治中毒性耳聋、降血脂等多种生物活性,开发前景广阔。本文对近年来骨碎补的化学成分、药理作用及临床应用研究进行综述,以期为骨碎补的进一步深入系统的研究和开发利用提供依据。  相似文献   
64.
65.
In HIV/AIDS research, few studies to date have evaluated ways to improve parental HIV disclosure practices using feedback from HIV-negative children who have recently experienced this event. We conducted semi-structured in-depth interviews with 20 children (aged 6–15) who were partially to fully aware of their parents’ HIV status in rural Guangxi, China. Of the 20 children, eight children who were of older age (11.38 years in average) endorsed parental HIV disclosure, five discouraged it and seven expressed uncertainty. Children’s different experiences and attitudes towards disclosure were seen to be associated with their family dynamics (especially the parent–child relationship), social support and care, experiences of stigma and discrimination, psychosocial suffering, comprehension of the disease and the children’s age. Our study contributes to building a child-centered comprehensive understanding for Chinese parental HIV disclosure. It is imperative that counselors and community advocates assess and help parents achieve optimal readiness preceding disclosure of their illness to their HIV-negative children.  相似文献   
66.
67.
Journal of Thrombosis and Thrombolysis - Amniotic fluid embolism (AFE) is a catastrophic condition in the peripartum period and still remains as a leading cause of maternal death. Although over 80%...  相似文献   
68.
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment.  相似文献   
69.
The retroviral protease of human immunodeficiency virus (HIV) is an excellent target for antiviral inhibitors for treating HIV/AIDS. Despite the efficacy of therapy, current efforts to control the disease are undermined by the growing threat posed by drug resistance. This review covers the historical background of studies on the structure and function of HIV protease, the subsequent development of antiviral inhibitors, and recent studies on drug-resistant protease variants. We highlight the important contributions of Dr. Stephen Oroszlan to fundamental knowledge about the function of the HIV protease and other retroviral proteases. These studies, along with those of his colleagues, laid the foundations for the design of clinical inhibitors of HIV protease. The drug-resistant protease variants also provide an excellent model for investigating the molecular mechanisms and evolution of resistance.  相似文献   
70.
肝癌是临床上常见的恶性肿瘤,因早期症状不典型,至发现时往往已为中晚期,失去最佳手术治疗时机和机会。作为非手术治疗之一的放射治疗技术,其发展在近年来已有了较大的进步。放疗包括体外放疗和体内放疗,皆具有一定的治疗效果和相对可控的不良反应。本文就肝癌放射治疗的应用进展作一综述。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号